Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects

被引:0
作者
Pandey, Swaroop Kumar [1 ]
Yadav, Neha [2 ]
Mishra, Anuja [1 ]
Sohal, Jagdip Singh [3 ]
Thakur, Komal [3 ]
Dwivedi-Agnihotri, Hemlata [2 ]
机构
[1] GLA Univ, Inst Appl Sci & Humanities, Dept Biotechnol, Mathura 281406, India
[2] Univ Delhi, Dept Biophys, South Campus, New Delhi 110021, India
[3] GLA Univ, Ctr Vaccine & Diagnost Res, Mathura, India
关键词
Pleura; mesothelioma; socioeconomic burden; asbestos; carbon nanotubes; INTENSITY-MODULATED RADIOTHERAPY; PHASE-II TRIAL; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; INTERVENTION SITES; ASBESTOS BAN; OPEN-LABEL; MULTICENTER; RADIATION; IMMUNOTHERAPY;
D O I
10.2174/0115733947315242240718074626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pleural malignancy is an aggressive malignancy of the pleural surface and is primarily associated with asbestos exposure. Malignant pleural mesothelioma (MPM) is an invasive form of mesothelioma and resistant to conventional therapy. Recently, it has also been reported that carbon nanotube (CNTs) exposure can induce inflammation and fibrosis of the pleura and induce tumor development pre-clinical model. Although several strategies like immunotherapy (Dendritic cells, immune checkpoint inhibitors, CAR-T cell therapy), and viral therapy are being employed for the management of MPM. However, poor prognosis and limited treatment options make the problem worse. Apart from clinical challenges, industrial and socioeconomic challenges are key factors for the patients as they are mainly industry workers or their associates. This article is focused on industrial, clinical and socioeconomic challenges associated with malignant pleural mesothelioma (MPM) patients and available opportunities.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Management of malignant pleural mesothelioma
    Hurmuz, Pervin
    THORACIC CANCER, 2010, 1 (02) : 53 - 61
  • [42] Turkish Clinical Guideline for Malignant Pleural Mesothelioma
    Metintas, Muzaffer
    EURASIAN JOURNAL OF PULMONOLOGY, 2015, 17 : 1 - 21
  • [43] Management of malignant pleural mesothelioma: have we made any progress?
    Hiddinga, B. I.
    Surmont, V. F.
    Van Meerbeeck, J. P.
    PANMINERVA MEDICA, 2013, 55 (02) : 157 - 173
  • [44] Malignant Pleural Mesothelioma
    Tsao, Anne S.
    Wistuba, Ignacio
    Roth, Jack A.
    Kindler, Hedy Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2081 - 2090
  • [45] Malignant pleural mesothelioma
    Boutin, C
    Schlesser, M
    Frenay, C
    Astoul, P
    EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (04) : 972 - 981
  • [46] Malignant pleural mesothelioma
    Gross-Goupil, M
    Ruffié, P
    BULLETIN DU CANCER, 1999, : 43 - 54
  • [47] Clinical diagnosis of malignant pleural mesothelioma
    Bianco, Andrea
    Valente, Tullio
    De Rimini, Maria Luisa
    Sica, Giacomo
    Fiorelli, Alfonso
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S253 - S261
  • [48] Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
    Bograd, Adam J.
    Suzuki, Kei
    Vertes, Eva
    Colovos, Christos
    Morales, Eduardo A.
    Sadelain, Michel
    Adusumilli, Prasad S.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (11) : 1509 - 1527
  • [49] Malignant pleural mesothelioma: an update on diagnosis and treatment options
    Kondola, Sanjana
    Manners, David
    Nowak, Anna K.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 275 - 288
  • [50] Malignant pleural mesothelioma: Computed tomography and correlation with histology
    Seely, Jean M.
    Nguyen, Elsie T.
    Churg, Andrew M.
    Mueller, Nestor L.
    EUROPEAN JOURNAL OF RADIOLOGY, 2009, 70 (03) : 485 - 491